Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Rating of “Moderate Buy” by Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $17.1667.

Several research analysts have commented on the company. Robert W. Baird cut their price objective on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 25th. Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a research note on Thursday, February 5th. They set an “overweight” rating for the company. HC Wainwright lifted their price target on Karyopharm Therapeutics from $8.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th.

Karyopharm Therapeutics Stock Performance

KPTI opened at $8.16 on Friday. The business’s 50-day simple moving average is $7.79 and its 200-day simple moving average is $7.32. Karyopharm Therapeutics has a one year low of $3.65 and a one year high of $10.99. The stock has a market capitalization of $184.91 million, a P/E ratio of -0.54 and a beta of 0.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.21. The business had revenue of $35.07 million for the quarter, compared to analyst estimates of $31.40 million. On average, equities research analysts forecast that Karyopharm Therapeutics will post -3.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada lifted its position in Karyopharm Therapeutics by 4.1% during the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock worth $336,000 after acquiring an additional 2,399 shares during the last quarter. Commodore Capital LP acquired a new position in Karyopharm Therapeutics during the 1st quarter worth $10,862,000. OMERS ADMINISTRATION Corp acquired a new position in Karyopharm Therapeutics during the 1st quarter worth $108,000. Renaissance Technologies LLC lifted its position in Karyopharm Therapeutics by 75.9% during the 1st quarter. Renaissance Technologies LLC now owns 105,414 shares of the company’s stock worth $587,000 after acquiring an additional 45,500 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new position in Karyopharm Therapeutics during the 1st quarter worth $66,000. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.